The scientific effort developing the A2-73 molecule was completed years ago. Hence, Anavex is a clinical stage biotech.
Other molecules are also developed and has preclinical scientific work complete. Taking these to the clinic cost money and attention, which will be available IMO only if A2-73 proves successful in the current trials.
Managing which and where to conduct clinical trials, their design and financial considerations falls under Missling as CEO.
For that and how to apply best practice the Anavex CEO has hired a team to complement his skills and experience most recently including Kaufmann as CMO.
With advice from the SAB etc., and I have no doubt with Missling’s active engagement and management, Anavex has taken an approach to learn as much as possible from data before moving ahead.
Controlled trials in two key conditions PDD and AD are now running in countries with excellent healthcare systems that practically and financially supports clinical trials allowing Anavex to deliver trial results at a fraction of the cost we usually see with biotechs that tend to fund their efforts through an IPO and a string of dilutive SPOs.
In addition two of the current 3 trials, in Rett and PDD, have been expanded to Australia.
I welcome all that and consider it very well done and different from any biotech I can think of.
Now we wait for results this and next year, which will be telling for the direction this investment is headed. With good results the market will react, I predict quite dramatically, because those results are likely indicative of outcomes in the P2b/3 AD trial.
Now of course there is no guarantee that the first trial readouts will be positive, but risk/reward ratio is looking good.
Trading in between is fine, but is not science or investing. It is an opportunity to tell world about one’s second to none time-money management skills - just as long as it doesn’t leave a no position situation when news hits.
